Saturday, March 19, 2011

Email to VA: Why Is VA Still Providing and Touting Flawed GWI Clinician Guide

The email below was sent to VA Chief of Staff John Gingrich’s point person on Gulf War veteran issues (COL Jeff Peters) tonight, March 18, 2011. 

It remains unclear why VA has a uniformed, active duty DoD military officer from DoD’s Office of Force Protection – the source of nearly all of the Gulf War veterans’ mistrust – as VA’s lead staff member on this veterans’ health issue.

--Anthony Hardie

======================

Col. Peters,
 
A few weeks ago following the most recent RAC-GWVI meeting, we discussed your assertion that there was a new Veterans Health Initiative (VHI) publication.  For those cc'ed on this email, the VHI has healthcare providers treating ill 1991 Gulf War veterans as its target audience.  Thereafter, you sent the email pasted below, to which I have to date received no response. 
 
Several weeks later, I note that the Gulf War VHI on va.gov/gulfwar is still the same 2001/02 VHI that everyone has been calling for the last several years for VA to remove because much if not most of it is seriously outdated, misleading, and in many cases now known to be false.    Here's the VA webpage on which it is touted and linked, for easy reference:  http://www.publichealth.va.gov/vethealthinitiative/gulfwar.asp
 
Among the most serious errors in VA's current PGW VHI, featured on your new Gulf War website, are:

  • A focus on "reassurance of patients" rather than providing treatment, or in the absence of effective treatments, explaining with honesty that there currently are none.  These statements alone beginning on page 27 and written by a psychiatrist who is still to this day open about his disbelief in GWI and quit the CDMRP GWIRP review panel last year because the other panelists refused to agree with him (Col. Chuck Engel, one of the supervisory officers reprimanded in the Fort Worth Islamist shooting incident).  This inappropriate monologue on communication with PGW patients goes on for seven pages -- more than is dedicated to any other topic in this VHI. 

It is this kind of lack of responsibility that continues to turn veterans against VA.  Why wouldn't it?

  • "Infectious diseases, however, have not been shown to be a major cause of chronic illnesses. After 10 years of intense clinical observation and study, it is increasingly unlikely that an infectious or immune process could cause serious health problems and remain undetected." -- This flies in the face of VA's recent presumptive service-connection of 9 endemic diseases for PG and Afghanistan veterans
  • IOM has found insufficient evidence on any PGW exposures -- obviously outdated and now false
  • Suggestions that GWI is the same as occurs after every war -- this is a myth scientifically refuted long ago
  • Most Gulf War health issues are diagnosable -- this stands in direct contradiction to IOM's GW Vol. 8, which finds 250,000 with chronic multi-symptom illness
  • GWI doesn't exist -- another myth, exploded by science and publicized by both RAC-GWVI and IOM
  • The falsehood that GWI is really one of 7 conditions:  FM, CFS, IBS, PTSD, Depression, Anxiety Disorder, Headache
  • No unusual risk of ALS -- Patently false
  • OP chemical warfare agents cause symptoms that are virtually identical to those caused by OP pesticides.  -- False

To keep this VHI -- which angered the entire GWI community when it was first released in 1998 and again in 2001/2001 -- on the VA website irrefutably demonstrates that VA continues to hold these flawed beliefs as current, accurate, and meaningful for VA and other healthcare providers. 
 
To make this more personal, can you imagine how insulted you would feel if you went to your doctor with a very real set of debilitating health symptoms, yet your doctor spent the entire appointment trying solely to "reassure" you as is carefully and extensively advised in VA's Gulf War VHI?
 
To keep this VHI on the VA website is not only a disservice to Gulf War veterans and their health care providers, but a slap in the face of every committee, researcher, and veteran who rightly called for its removal.
 
It should go without saying, but having such very bad information actively being provided by VA is worse than having no information at all.
 
What will it take for VA to listen and finally remove this highly flawed VHI as has been repeatedly recommended?  Please advise me.
 
Anthony Hardie
Madison, Wis.
 
 
----------------
 
On Mon, Feb 28, 2011 at 2:48 PM, Peters, Jeff <Jeff.Peters@va.gov> wrote:
 
Hi Tori,
 
I had a question today about the new VHI I did know the answer to and wanted your help.  I am looping Anthony Hardie, who asked the question, into the conversation.  Regarding the new GW VHI how did we construct the education program so it was more relevant to the 1990-1991 GW Cohort?  Thanks Tori,
 
jeff
 
Jeffrey Peters
Special Assistant
Office of the Secretary
Department of Veteran Affairs
202.461.4814
jeff.peters@va.gov

Thursday, March 17, 2011

CDMRP-Funded Mitochondrial Dysfunction GWI Study Recruiting in Atlanta, Ga.

Study Recruitment Material - Mechanisms of Mitochondrial Dysfunction in Gulf War Syndrome
Funding: DOD, GW080138
Principal Investigator: John Shoffner, M.D.

Study Rationale:

Gulf War syndrome (GWS) is associated with increased incidences of amyotrophic lateral sclerosis, pain syndromes, muscle complaints that include fatigue and myalgias, as well as other neurological symptoms. Approximately 100,000 individuals of the 700,000 veterans deployed in 19901991 Gulf War have medical complaints consistent with GWS. Clinical manifestations are similar to those identified in Chronic Fatigue Syndrome (CFS). Abnormalities in the part of the cell known as mitochondria have been delineated in GWS and CFS. We propose that GWS is determined by a complex interaction of variables that impair mitochondrial function that include genetic susceptibility, pre-Gulf War exposures, Gulf War associated exposures, and aging. This study will be the first comprehensive investigation of mitochondrial function in GWS. Our objective is to establish the cause for symptoms in affected veterans, develop testing that can more easily identify GWS, and ultimately develop treatment protocols for GWS.

The mitochondria have many functions that include changing the foods we eat into a usable form of energy known as ATP (adenosine triphosphate). All the cells of our body use this energy to run the biochemical reactions that allow our cells to function properly. Hence, the mitochondria act as tiny power plants inside of every cell. These power plants also utilize about 95% of the oxygen that we breathe. When the energy (ATP) is produced at normal levels, the cells function normally. When the energy (ATP) is reduced, the cells develop a variety of problems (analogous to a city during a brown out where energy dependent functions begin to fail). The central nervous system and muscle are often affected. These diseases can have their onset at any age and can even be triggered by exposure to certain chemicals and drug exposures. Multiple lines of evidence from the literature and from patients studied in our laboratory suggest that the mitochondria are not functioning properly in GWS and in CFS. Hence, detailed investigation of mitochondrial dysfunction in GWS is a priority.

Over the last two decades, our group has been dedicated to working with patients with mitochondrial defects. Over the years, we described many inherited mutations and biochemical defects that impair mitochondrial function. Our proposal is unique in that we integrate a variety of specialized laboratory techniques that characterize mitochondrial function into a comprehensive investigation. Our proposal is designed to characterize mitochondrial function in 50 veterans with GWS using blood and skin cells.

We will be investigating the skin and blood cells by characterizing precisely how mitochondria are working through detailed investigation of mitochondrial enzyme function, of mitochondria within living cells, of mitochondrial proteins, and of mitochondrial genes.

  • Please review the consent form for the study for a complete discussion of the study procedures and risks.
  • Participation in the study will take approximately 1.5-2.0 hours of your time.
  • The procedures performed during this visit are a clinical evaluation by Dr. Shoffner, drawing blood, and a small skin biopsy from the arm.
  • Once again the consent form discusses the study and the procedures in detail.
  • Dr. Shoffner will answer your questions about the study.

----------

MORE INFORMATION

Tuesday, March 15, 2011

VA Issues New FAST Letter on Iraq, Afghanistan, Gulf War Claims

clip_image002

DEPARTMENT OF VETERANS AFFAIRS

Veterans Benefits Administration

Washington, D.C. 20420

March 15, 2011

Director (00/21)

All VBA Regional Offices and Centers Fast Letter 11-09

SUBJ: Procedures for Rating Infectious Diseases Presumed to Be Related to Gulf War, Iraq, and Afghanistan Service under 38 CFR § 3.317(c).

Purpose

This letter provides guidance on rating disability and death claims for service connection based upon specified infectious diseases that are presumed to be related to Gulf War, Iraq, and Afghanistan service.

Gulf War Presumptive Infectious Diseases

38 CFR § 3.317(c) was revised effective September 29, 2010. The revised regulation provides for establishing service connection on a presumptive basis for the following infectious diseases: Brucellosis, Campylobacter jejuni, Coxiella burnetii (Q fever), Malaria, Mycobacterium tuberculosis, Nontyphoid Salmonella, Shigella, Visceral leishmaniasis, and West Nile virus.

A new special issue (Gulf War Presumptive) is added to RBA2000 as part of the February 26-27, 2011, weekend installation. Each of the specified infectious diseases was added to RBA2000 as a special issue basis for the Gulf War Presumptive special issue. Please see enclosures 1 and 2 for instructions on when and how to use the new Special Issue and Special Issue Basis.

Questions

E-mail questions regarding this letter to: VAVBAWAS/CO/215/RBA2000.

/S/

Thomas J. Murphy

Director

Compensation and Pension Service

Enclosure 1 – Rating Decision Procedures

Enclosure 2 – Rating Decision Analysis Text

--------------

Enclosure 1 – Rating Decision Procedures

Gulf War Presumptive Infectious Diseases

Field users will utilize the “Gulf War Presumptive” Special Issue and the appropriate Special Issue Basis when rating the specified infectious diseases claimed as presumptively due to Gulf War service. RBA2000 will generate proper text for all grants and for most denials. However, when service connection is denied as not established by presumption and when service connection for the cause of death is denied, the field user must manually edit the RBA2000-generated text. The field user must always edit the generated text (as appropriate) so that it is claim specific and fully explains the decision to the claimant.

Note: When multiple special issues apply to a claim, the Gulf War Presumptive special issue must be added last to ensure proper text generation. For example, if the Veteran is also an ex-prisoner of war, select the POW Special Issue and Special Issue Basis before selecting the Gulf War Presumptive Special Issue to generate the POW text first. This ensures all appropriate text is included in the narrative.

Rating Decision Procedures – Live Service Connection

When rating one of the specified infectious diseases claimed as due to Gulf War service, the field user must select “Gulf War Presumptive” from the drop-down Special Issue Information List on the Enter Disability Ratings screen as shown in the screenshot below.

clip_image004

Once this entry has been selected, the Special Issue Basis field is enabled, and the field user must select the appropriate infectious disease from the drop-down list as shown in the screenshot below.

clip_image006

After completing all entries, click the Accept button to generate the text (an additional text selection box may appear depending upon the decision entered, but that is the same functionality as currently exists).

For all grants and denials of service connection (other than a denial as not established by presumption), the generated text should be correct and ready for the field user to customize for the specific claim that is being rated.

For a denial of service connection as not established by presumption, the generated analysis text must be deleted and replaced with the appropriate text from Enclosure 2. The “Issue” text and “Decision” text should be correct but must still be reviewed and edited, as necessary.

The Analysis text will vary based upon the reason(s) for the denial. There is a general paragraph that must be used for all issues and then one or more specific denial reason paragraphs must be added based upon the denial reason(s). Please see Enclosure 2 for the general paragraph and the specific denial reason paragraphs. Note that these paragraphs require the field user to enter information such as the disability name, date, etiology, etc.

Specific denial paragraphs are available for the following reasons:

  • All Other Conditions – Not Within 1 Year
  • Illness Not Chronic
  • Less Than 10 Percent Disabling
  • Malaria - Not Within Time Period

· No Diagnosis

  • No Nexus
  • No Qualifying Period Of Service
  • Not SC

· Other Etiology

  • Supervening Condition Or Event
  • Willful Misconduct

Rating Decision Procedures – Service Connection for Cause of Death

When completing a cause of death rating claimed as due to infectious disease under 38 CFR § 3.317(c), the field user must select “Gulf War Presumptive” from the drop-down Special Issue Information List on the Enter Death Ratings screen as shown in the screenshot below.

clip_image008

Once this entry has been selected, the Special Issue Information Basis field is enabled and the field user must select the appropriate infectious disease from the drop-down list as shown in the screenshot below.

clip_image010

After completing all entries, click the Accept button and then the OK button to generate the text (an additional text selection box may appear depending upon the decision entered, but that is the same functionality as currently exists).

For all grants of service connection, the generated text should be correct and ready for the field user to customize for the specific claim that is being rated.

For a denial of service connection for the cause of death, the generated analysis text must be deleted and replaced with the appropriate text from Enclosure 2. The “Issue” text and “Decision” text should be correct but must still be reviewed and edited, as necessary.

The Analysis text will vary based upon the reason(s) for the denial. There is a general paragraph that must be used for all issues and then one or more specific denial paragraphs must be added based upon the denial reason(s). Please see Enclosure 2 for the general paragraph and the specific denial reason paragraphs. Note that these paragraphs will require the field user to enter information such as the disability name, date, etiology, etc

Specific denial paragraphs are available for the following reasons:

· No Diagnosis

· No Nexus

· Not SC

.


Enclosure 2 – Rating Decision Analysis Text

Rating Decision Text – Live Service Connection

General denial paragraph for all issues of denial of service connection as not established by presumption:

Under the authority granted by 38 U.S.C. §§ 1117 and 1118, VA has determined that presumption of service connection may be established for certain infectious diseases based on active military, naval, or air service in the Southwest Asia theater of operations during the Persian Gulf War or a period of active military, naval, or air service in Afghanistan on or after September 19, 2001. These diseases include Brucellosis, Campylobacter jejuni, Coxiella burnetii (Q fever), Nontyphoid Salmonella, Shigella, and West Nile virus, which must become manifest to a degree of ten percent or more within 1 year from the date of separation from a qualifying period of service; Malaria, if the disease becomes manifest to a degree of ten percent or more within 1 year from the date of separation from a qualifying period of service or at a time when standard or accepted treatises indicate that the incubation period commenced during a qualifying period of service; and Visceral leishmaniasis and Mycobacterium tuberculosis, for which there is no time limit to become manifest to a degree of ten percent or more.

Text for specific denial reasons:

All Other Conditions – Not Within 1 Year

Service connection for {drop in claimed disability} is denied because there is affirmative evidence that the disease did not become manifest to a degree of ten percent or more within one year from the date of separation from a qualifying period of service.

Illness Not Chronic

The disability must have persisted for a period of at least six months. Presumptive service connection for {drop in claimed disability} is denied since this disability first manifested on {date} and lasted less than six months.

Less Than 10 Percent Disabling

Presumptive service connection for {drop in claimed disability} is denied because this disability has not become manifest to a degree of 10 percent or more disabling.

Malaria - Not Within Time Period

Service connection for malaria is denied because there is affirmative evidence that the disease did not become manifest to a degree of ten percent or more within one year from the date of separation from a qualifying period of service or at a time when standard or accepted treatises indicate that the incubation period commenced during a qualifying period of service.

No Diagnosis

Presumptive service connection for {drop in claimed disability} is denied because the evidence of record fails to establish a diagnosis for this disability.

No Nexus

The available scientific and medical evidence does not support the conclusion that {drop in claimed disability} is associated with the veteran’s active military, naval, or air service in the Southwest Asia theater of operations during the Persian Gulf War or a period of active military, naval, or air service on or after September 19, 2001, in Afghanistan.

No Qualifying Period Of Service

Presumptive service connection for {drop in claimed disability} is denied because the evidence of record reflects no qualifying period of service.

Not SC

Presumptive service connection for {drop in claimed disability} is denied since this disability was not incurred in or aggravated by active military, naval, or air service in the Southwest Asia theater of operations during the Persian Gulf War or on or after September 19, 2001, in Afghanistan.

Other Etiology

Service connection under this provision is precluded if there is affirmative evidence that the disability was unrelated to service in the Southwest Asia theater of operations during the Persian Gulf War or a period of active military, naval, or air service on or after September 19, 2001, in Afghanistan. Service connection for {drop in claimed disability} is denied because evidence establishes that this disability resulted from {enter etiology}.

Supervening Condition Or Event

Service connection is denied because there is affirmative evidence that {drop in claimed disability} was caused by a supervening condition or event that occurred between the veteran’s most recent departure from a qualifying period of service and the onset of the disease.

Willful Misconduct

Service connection is denied because there is affirmative evidence that {drop in claimed disability} is the result of the veteran’s own willful misconduct or the abuse of alcohol or drugs.

Rating Decision Text – Service Connection for Cause of Death

General denial paragraph for all issues of denial of service connection for the cause of death:

Under the authority granted by 38 U.S.C. §§ 1117 and 1118, VA has determined that presumption of service connection may be established for certain infectious diseases based on active military, naval, or air service in the Southwest Asia theater of operations during the Persian Gulf War or a period of active military, naval, or air service in Afghanistan on or after September 19, 2001. These diseases include Brucellosis, Campylobacter jejuni, Coxiella burnetii (Q fever), Nontyphoid Salmonella, Shigella, and West Nile virus, which must become manifest to a degree of ten percent or more within 1 year from the date of separation from a qualifying period of service; Malaria, if the disease becomes manifest to a degree of ten percent or more within 1 year from the date of separation from a qualifying period of service or at a time when standard or accepted treatises indicate that the incubation period commenced during a qualifying period of service; and Visceral leishmaniasis and Mycobacterium tuberculosis, for which there is no time limit to become manifest to a degree of ten percent or more.

Text for specific denial reasons:

No Diagnosis

Service connection for cause of death based on active military, naval, or air service in the Southwest Asia theater of operations during the Persian Gulf War, or a period of active military, naval, or air service on or after September 19, 2001, in Afghanistan, is denied. The evidence of record does not show diagnosis of a condition for which VA has found a positive association exists between service in Southwest Asia during certain periods and subsequent development of the condition.

No Nexus

Service connection for cause of death from {drop in Cause of Death} is denied because the available scientific and medical evidence does not support the conclusion that the cause of death is associated with active military, naval, or air service in the Southwest Asia theater of operations during the Persian Gulf War or a period of active military, naval, or air service on or after September 19, 2001, in Afghanistan.

Not SC

There is no basis in the available evidence of record to establish service connection for cause of death from {condition name}. This condition was not incurred in or aggravated by active military, naval, or air service in the Southwest Asia theater of operations during the Persian Gulf War or on or after September 19, 2001, in Afghanistan.

Monday, March 14, 2011

AFP: Pain Monitor, March 2011

PAIN MONITOR
March 2011

Forward to a Friend

Having Trouble Viewing this Email? Click Here

Action of the Month: Ask 5 People you Know to Join APF Today
Beginning this month, APF will feature an Action of the Month to engage you and those in your community to SPEAK OUT for the rights of people with pain. Forward this message to five or more of your friends and family members and ask them to join APF. The larger our number, the greater our influence! More info>>

NEWS

Pain is Tough to Treat
Doctors were harder on themselves than patients were when it came to judging their ability to minimize the pain, discomfort, or disability caused by a condition. Only 37 percent of physicians thought they were "very" effective, though 60 percent more thought they were "somewhat" effective. But 79 percent of patients said their doctor helped to minimize their pain or discomfort.

FDA LogoRisk of Oral Birth Defects in Children Born to Mothers Taking Topiramate
New data suggest that topiramate (topamax) increases the risk for the birth defects cleft lip and cleft palate in babies born to women who use the medication during pregnancy, the U.S. Food and Drug Administration said today.

Healing the Hurt
Some hurts are forever. But now science is pushing back.

Adverse Effects Weigh Heavily in Patients’ Medication Decisions
Adverse effects hold greater sway than the magnitude of potential benefits on older patients’ willingness to take medications for primary prevention of cardiovascular disease, researchers found.

UN Drugs Board Decries Poor Access to Pain Relief
More than 80 percent of the world's people have insufficient or no access to pain relief medications and are suffering unnecessarily because of it.

hispanic guyArthritis Takes Varying Toll on Hispanics
Rates of arthritis vary among different Hispanic groups but the overall effects of the disease appear to be substantial across groups, according to an analysis of national CDC survey data.

Pain, Persistence, Family: Sickle Cell Disease
How do you live with a disease that can cause sudden episodes of extreme pain? How does a family manage the needs of a child with a chronic, untreatable illness? These are among the questions that people facing a diagnosis of sickle cell anemia have to answer.

The End of Ouch?
Historically, if people were not in immediate medical danger, their pain was considered an unfortunate side effect or a collateral consequence of solving a greater problem.

For Tendon Pain, Think Beyond the Needle
Two time-honored remedies for injured tendons seem to be falling on their faces in well-designed clinical trials.

back painBack Pain Has Been Around for 4 Million Years, Scientists Say
In findings presented in a talk at Cambridge University, researchers challenged the notion that a sedentary lifestyle is to blame for spine problems.

NSAID Use Tied to Men's Sexual Performance
The regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with higher odds of erectile dysfunction, a cross-sectional study showed.



APF NEWS

Taking an Opioid? APF Unveils New Worksheets to Help
If you are prescribed an opioid for pain relief, there are many things you need to know. Two new handouts — Chronic Opioid Therapy: Preparing for Your Appointments and Opioid Dos and Don’ts to Help Avoid Problems will help you prepare for follow up medical appointments and give you tips for staying safe. Learn More >>

APF Releases Report on Cancer Pain
The American Pain Foundation (APF) is proud to release its report “Breakthrough Cancer Pain: Mending the break in the continuum of care.” This 24-page document builds upon our initial call to action released last fall.


APF ACTION NETWORK

10,000 Voices Campaign
The 10,000 Voices campaign needs you to add your voice to the Virtual Wall of Voices. Your stories of struggle, hope and inspiration will be used to illustrate the range of experiences with pain management in America and inspire others to overcome the barriers that they face in their pain journey.

SPEAK OUT for the Rights of People with Pain!

Great news from Nebraska! The National Hospice and Palliative Care Organization (NHPCO) recently announced that the Nebraska Hospice and Palliative Care Association’s Jennifer Eurek, CSW, also an AN leader for Nebraska, has been appointed as the Central Plains regional representative for the We Honor Veterans Campaign, a national Veterans awareness campaign! Please visit www.nehospice.org for more information.

Georgia’s AN team attended the 2011 Atlanta Summit on Prescription Drug Abuse. Ashley Mahoney (Georgia AN leader) testified at the meeting presenting the voice of a person living with pain who requires  pain medicine and uses it effectively and responsibly to manage her pain. For more about this meeting please visit this site

Announcing Two New APF State Leaders
Angie Gravois, RN, joins us from Mississippi. Angie is both a person with pain and the health care provider. Angie has been active in awareness campaigns, research, and education on issues of fibromyalgia, and other diseases causing chronic pain, as a health care professional, a patient, and an advocate.  

Zulma Pagan is a new leader from Puerto Rico. She is a person with pain who has been living with fibromyalgia for over 14 years. She is the founder and president of a fibromyalgia support group and has campaigned for increased visibility of fibromyalgia issues in policy, healthcare, and research within the U.S and in Latin American countries.


CONNECT

PainAid Online Support Community
PainAid provides chat rooms (regularly scheduled chats on different issues), discussion boards (threaded message boards on a broad variety of topics), and the Ask the Experts feature (pose questions to licensed health care professionals). PainAid is staffed by highly qualified volunteers with a range of backgrounds, all of whom either live with chronic pain or care for people who do. Visit PainAid for more information.

Voices of People with Pain
If you are a person with pain or know someone who lives with pain, we invite you to share your story. View others' stories or share your own.

Webinar and Teleconference Replays
All APF webinars and teleconferences are archived for on-demand viewing. Make sure to check out our chat transcripts and join us at PainAid for future daily and special chats. Sign up to receive notifications of future webinars and teleconferences.

Other ways to get involved in our efforts:


SPOTLIGHT ON PAIN

The American Pain Foundation “Spotlights” are educational campaigns that highlight specific pain conditions or populations of people that experience pain. Spotlights bring focus to an issue offering a variety of ways for people to learn more about the topic, gain support, and take action. Click here for more information about our spotlights.

Back Pain

Treating Back Pain
Tips for the best solutions and treatments. (Video)

Taking Short Breaks Alleviates Back Pain
Preventing back pain might be as easy as getting up from your chair and walking every couple of hours.

The Claim: Back Pain Runs in Families
Heavy lifting, overuse and middle age are some of the most familiar risk factors for lower back pain. But for many people, predicting a lifetime of lumbar trouble could be as simple as consulting the family tree.

Cancer Pain

One-Third of Cancer Patients on Opioids Suffer Cognitive Problems
About a third of cancer patients taking opioid painkillers experience cognitive problems such as confusion, disorientation and forgetfulness, a new study finds.

Fibromyalgia

Increased Risk for Death From Suicide and Accidents Seen in People with Fibromyalgia
Although patients with fibromyalgia are not at an overall increased risk for mortality, they are at greater risk for suicide and accidents, according to a large observational study presented at the annual meeting of the American College of Rheumatology.

Let's Talk Pain

Patients Unable to Simplify Medication Schedules Themselves
Few people were able to translate prescription instructions so that they minimized the number of times a day they had to take medication, researchers found.

Shingles

People with COPD May Have Risk of Shingles
Researchers suggest people with chronic obstructive pulmonary disease get shingles vaccine.

Yoga

Believe in the Power of Movement
An increasing number of studies emphasize the health benefits of physical activity. Yoga, an ancient practice aimed at achieving tranquility and increasing flexibility, muscle tone, balance and strength is rapidly becoming the activity of choice for a large number of people who suffer from rheumatoid arthritis and other autoimmune diseases.


SCIENCE & MEDICINE

Managing CSF Leaks During Spinal Cord Stimulation Trial
A cerebrospinal fluid leak can be a headache for anesthesiologists performing a spinal cord stimulator trial, not to mention a trigger for an excruciating post-meningeal puncture headache for the patient.

UC Davis Pain Research May Pave the Way to Understanding and Controlling Chronic Pain
Researchers at the University of California, Davis have discovered a “cross-talk” between two major biological pathways that involve pain. This research may pave the way to new approaches to understanding and controlling chronic pain.


COMPLEMENTARY MEDICINE

yogaposeAlternative Treatment Helps People with Chronic Back Pain
Non-aggressive therapy strengthens bad backs.


PROFESSIONAL TRAINING OPPORTUNITIES

Responsible Opioid Prescribing in the Era of REMS Dinner Dialogues Series
The interactive Dinner Dialogues series discusses critical thinking strategies to help you optimize analgesia and facilitate safe and appropriate use of opioid therapy in your practice. These independent medical education activities are sponsored by the American Pain Foundation (APF) and supported through an educational grant from Endo Pharmaceuticals. Click here to register today!

Social Work Fellowship in Palliative and End-of-Life Care
A postgraduate social work fellowship in palliative and end-of-life care is available through the Department of Pain Medicine and Palliative Care at Beth Israel Medical Center. The fellowship program provides a supervised experience in the multidimensional assessment and care of patients, in multiple practice sites (an inpatient pain, palliative care and hospice unit, inpatient consultation service and an ambulatory practice) at various points along the continuum of life-threatening illness. Fellows participate in interdisciplinary rounds, case discussions, didactic conferences and departmental meetings with the focus on multidimensional approaches to symptom management, palliative and end-of-life care.

Learning will be complemented by access to interdisciplinary experts and resources such as the departmental multimedia resource center where a broad range of educational materials is available. Designed to develop role models, leaders, and mentors, the social work fellowship was established with a grant from the Open Society Institute Project on Death in America through their Social Work Leadership Award and receives ongoing support through the Barbara Zirinsky Fund. The program is offered on a full-time basis for one year and includes stipend and benefits. Applications are currently being accepted and are available at this link: http://www.stoppain.org/for_professionals/content/information/training.asp

Deadline for completed applications is April 1, 2011 with fellowship year to begin in June 2011 or shortly thereafter.

Mayday Pain & Society Fellowship: A Media and Policy Initiative
The Mayday Fund, a New York City-based foundation dedicated to alleviating the incidence, degree, and consequence of human physical pain, is interested in providing new leaders in the pain field with tools that will enable them to reach the broader public.

The Mayday Pain & Society Fellowship: A Media and Policy Initiative is a fellowship program to train physicians, nurses, pharmacists, social workers, basic, translational and clinical scientists, policy experts and legal scholars in the pain management community to go beyond their own professional pursuits to become leaders and advocates for change in the pain field in the United States and Canada. The deadline for applying to the 2011-12 program is Wednesday, June 15, 2011. More info >>


EVENTS

Public

RSD/CRPS Awareness Quilt Project
An ongoing project to raise awareness about chronic pain conditions, especially RSD.  The organizers are gathering quilt squares to make a pain awareness quilt that will travel across the United States. For more information, visit the Facebook page.

April 28, 2011
Wounded Warrior Care- Rediscovering the Meaning of Healthcare in America Today
Washington, DC

March 18, 2011
RALLY for pain care in WA State

June 5, 2011
National Cancer Survivors Day

June 2-4, 2011
Amputee Coalition National Conference
Kansas City, MO

Professional

March 24-27, 2011
American Academy of Pain Medicine Annual Meeting
Washington, DC

April 28, 2011
RADARS System Annual Meeting
Bethesda, MD

May 19-21, 2011
American Pain Society
Austin, TX

June 2 - 5, 2011
53rd Annual Scientific Meeting American Headache Society
Washington, DC

Sept 7-10, 2011
American Society for Pain Management Nursing
Tucson, AZ

Sept 7-10, 2011
PainWeek
Las Vegas, NV

Sept 14-17
American Academy of Family Physicians Scientific Meeting
Orlando, FL

September 20 - 23, 2011
22nd Annual Clinical Meeting
American Academy of Pain Management
Exploring the Science Practicing The Art
Las Vegas, NV

For more events happening around the country or to submit an event of your own, please visit our Events page.


Thank you to our medical/science editor Robert Twillman, PhD.


The Pain Monitor is a monthly electronic publication of the American Pain Foundation. We want to keep you abreast of recent media attention given to topics that are related to pain care or living with pain. This information is provided for educational and information purposes only. Readers may wish to print the information and discuss it with their doctor. Always consult with health care providers before starting or changing any treatment. Above are links to news articles, feature stories and timely information that have come to our attention. Please pass them along to others who might benefit. We encourage you to send any comments you may have to the authors or publishers directly. Every voice counts when working towards improving pain care in our nation.

The American Pain Foundation is an independent, nonprofit organization that relies upon private donations to fund its programs, services and distribution of educational materials. There are millions of people who live with unrelieved chronic pain. If you can help, please make a donation to the American Pain Foundation. For other ways you can support APF’s work, please visit our website at www.painfoundation.org.

Sunday, March 13, 2011

Chris Kornkven: Continuing the Battle for Gulf War Veterans

Written By the Staff of the Congressionally Directed Medical Research Program (CDMRP)

Chris Kornkven

Chris Kornkven is a Gulf War veteran who, since his homecoming in 1991, has endured debilitating health effects from his military service. Chris noticed his symptoms-chronic fatigue, arthritis-like pain, and stiffness in his major joints, along with significant short-term memory problems and long-term memory retention-while he was still in the Gulf War zone. He assumed that these health problems were endemic to the Gulf area and that they would fade upon his return home, but he became concerned when they did not subside. In 1992, after hearing that other Gulf War veterans were reporting the same conditions, and that these conditions were persisting and not improving, Chris became active in veterans' health issues.

Chris remarks that, for the past almost 20 years, his joint pain has been a daily reminder of his military service. Ordinary movements-walking, climbing steps, kneeling, or playing with his children-keep him in the grip of pain. He reports that his fatigue is unrelenting and is not relieved by sleep. At times, sheer exhaustion overcomes him when he is at the wheel of his car, and he has had to pull over to the side of the road just to rest. His problems with memory have been as severe as his joint pain and fatigue. Chris admits, "Even simple tasks or appointments that should be easily remembered require compensating in some manner, either by taking considerable notes, as when I first returned [home], or in using a personal digital assistant, as I do these days. Although coaching and compensating have aided me, significant activities that I have been involved in are forgotten as if I never participated."

Concerns with how widespread health effects were within the Gulf War veteran community prompted Chris and fellow veterans to found the National Gulf War Resource Center, Inc. in 1995. The organization was created to provide a clearinghouse of information for fellow veterans, their family members, caregivers, or others involved with Gulf War veterans. Chris served as Interim President of the organization, then was elected national President serving from 1996 until 2001. In that capacity, Chris has provided numerous media interviews and has met with Congressional, Pentagon, and Veterans Affairs officials, veterans service organizations, as well as veterans and their families, striving to ensure that veterans receive the medical care they earned.

Knowing firsthand the devastating effects of Gulf War Illness, Chris is committed to finding ways of improving the quality of life for ill Gulf War veterans. In his search for answers, Chris has worked with the National Gulf War Resource Center, Inc., Gulf War Veterans of Wisconsin, Veterans of Modern Warfare, Veterans of Foreign Wars, Disabled American Veterans, and the Gulf War Illness Research Program, which is under the umbrella of the U.S. Department of Defense Congressionally Directed Medical Research Programs (CDMRP).

After years of working with veterans, Chris relishes the opportunity to have a seat at the table when discussing research projects as a Consumer Reviewer for CDMRP. "It gives me considerable satisfaction when reading through these projects the level of commitment from those submitting proposals. They truly are as interested in finding solutions to these medical problems as we have been, and our opinions as veterans are being heard."


Source:  Congressionally Directed Gulf War Illness Medical Research Program, http://cdmrp.army.mil/cwg/stories/2010/kornkven_profile.shtml

Photos and text used with permission of  Mr. Chris Kornkven.

Friday, March 11, 2011

Memory Builder Tool Available Online

Memory problems, including short-term and working memory deficits are among the most commonly reported neurologic symptoms among Gulf War veterans suffering from chronic multi-symptom illness (Gulf War Illness), multiple sclerosis (MS), fibromyalgia (FMS) and other neurologic disorders.

A great new memory building tool is now available online, courtesy of MS ActiveSource.

--Anthony Hardie

Thursday, March 10, 2011

Neurology Now: Fibromyalgia is a True Neurologic Disorder

Editor’s note:  Fibromyalgia is a very real neurologic condition that affects thousands of Gulf War veterans.  The federal VA has determined that Fibromyalgia is a presumptive condition for service-connected disability for Gulf War veterans.

--Anthony Hardie

------------------------------

Neurology Now: September/October 2009 - Volume 5 - Issue 5 - p 29-32.  Feature.

 

Fibromyalgia: Is Fibromyalgia Real?

SHAW, GINA

Abstract

A growing body of information suggests fibromyalgia is a true neurologic disorder.

Like many of his colleagues, John Kissel, M.D., used to think that fibromyalgia wasn't a real condition. Dr. Kissel, a neurologist and the co-director of the MDA/ALS Center at Ohio State University, thought it was a wastebasket diagnosis-a dumping ground for malingering, drug-seeking patients with unexplained pain, fatigue, and depression.

Then he saw patients that began to change his mind. He still remembers one woman in her 40s, a professional trial attorney from Columbus, OH. She had developed debilitating fatigue and horrible muscle pain and tenderness about a month after getting over a mild case of the flu.

After performing a number of tests, I went in to speak with her and mentioned fibromyalgia, Dr. Kissel recalls. She asked, 'What's that?' I said, 'You haven't heard of fibromyalgia? People are talking about it all over the place.' She said to me, 'I work 14 hours a day as a trial attorney-I don't do outside reading.' She wasn't depressed. She was still working. But she had all the typical symptoms of fibromyalgia. That was a formative experience in my thinking about the condition.

Today, more and more neurologists are coming around to the idea that fibromyalgia is a real disorder, and one that should be managed, or at least co-managed, by neurologists who care for chronic pain-not only the rheumatologists who originally identified the condition some 100 years ago.

Neurologists have become more educated about the diagnosis and treatment of fibromyalgia. - LYNNE MATALLANA, FOUNDER OF THE NATIONAL FIBROMYALGIA ASSOCIATION

Fibromyalgia has long presented a puzzle for doctors. It's considered a syndrome-a collection of related symptoms and problems without an identifiable cause-rather than a disease. Those related symptoms include:

* Chronic widespread pain, often accompanied by numbness, tingling, and burning

* Multiple tender points throughout the body

* Severe fatigue

* Sleep problems

Pain networks in the brains of fibromyalgia patients seem to be more easily activated than in people without the disorder.

To be diagnosed with fibromyalgia, a person must have had widespread pain in all four quadrants of the body for at least three months, and tenderness or pain when pressure is applied in at least 11 of 18 identified tender points.

Fibromyalgia was originally thought to be a rheumatologic condition because-like diseases such as rheumatoid arthritis-it is characterized by musculoskeletal pain. But research has since shown that there are no abnormalities in the musculoskeletal system in people with fibromyalgia. Instead, the problem appears to lie in the pain processing pathways of our central nervous system-the bailiwick of neurologists. Today, both rheumatologists and neurologists treat fibromyalgia.

The National Fibromyalgia Association estimates that between three percent and six percent of the population has fibromyalgia-mostly women, but some men and children as well. However, with a flimsier body of research than many other chronic conditions and no blood test to diagnose the disorder, controversy has swirled around fibromyalgia for years. It's also easily confused with other conditions, such as rheumatoid arthritis and lupus (in fact, some patients have both).

Lynne Matallana, the founder and president of the National Fibromyalgia Association, originally saw a rheumatologist for her fibromyalgia. Recently she has also been seeing a neurologist to help with the overlapping conditions, such as migraines and restless leg syndrome, that also cause her distress.

Just like everyone with fibromyalgia, I have to deal with comorbid conditions that are often treated by neurologists, Matallana says. When I started experiencing insomnia and daytime sleepiness, for example, I was referred to a neurologist who specialized in sleep disorders. Unlike several years ago, neurologists have become more interested and educated about the diagnosis and treatment of fibromyalgia. As a patient this is extremely exciting because they bring a new perspective.

 

LONGSTANDING SKEPTICISM

In the past, there has been legitimate reason for skepticism about fibromyalgia, Dr. Kissel acknowledges. The majority of research in fibromyalgia was not adequate, he says. Studies would pick some parameter and look at it only in patients with fibromyalgia and sometimes in normal controls, without comparing them to people with other chronic pain conditions, patients with depression, or to patients with other muscle diseases.

What's more, some physicians tended to view it as a grab-bag condition, diagnosed only when the doctor couldn't find anything else. Patients would come in and say, 'I have muscle pain.' The doctor would do all kinds of tests-electromyography [a test for abnormal electrical activity in the muscles], blood work, muscle biopsies, and imaging, and if all that was negative, then voilà, it was fibromyalgia, he says.

But that's not the way you diagnose, Dr. Kissel stresses. It's as if someone came in with a classic migraine headache and you gave the patient scans, brainwave tests, and arteriograms [imaging of the blood vessels], and if you still didn't know what it was, you said they had migraine. You diagnose migraine by what patients tell you and the way they look in the exam room, and that's the way you diagnose fibromyalgia, too.

The fact that abnormalities don't show up on standard neurological tests like electromyelograms and nerve-conduction studies (tests that measure how fast electrical impulses travel between nerves) is not evidence that fibromyalgia doesn't exist, says John Farrar, M.D., Ph.D., a neurologist and pain specialist at the University of Pennsylvania School of Medicine. There may be a few people in the world who complain of [fibromyalgia] in order to get drugs and attention, but the number of real malingerers is relatively small. The patients I see have very real pain, and it's up to us as doctors to figure out what the underlying major contributors to that pain are.

It hasn't just been doctors who are skeptical of fibromyalgia-many patients have been, too. Just recently I saw two patients who had both been to the Cleveland Clinic previously. One was the wife of a physician. They had both been told that they had fibromyalgia but neither wanted to accept it, despite the fact that they had all the criteria, says Dr. Kissel. Probably three-quarters of the patients I now see with fibromyalgia have been diagnosed by another doctor, but neither the doctor nor the patient is satisfied with the diagnosis. They want another diagnosis that they think will be more treatable.

 

NEW CLUES FROM BRAIN RESEARCH

New and better research pointing to possible underlying causes of fibromyalgia seems to be winning over at least some of the skeptics. Using tools like functional MRI, which show the brain's response to pressure and heat stimuli, researchers have been able to measure how people with fibromyalgia process stimuli like pain and pressure. Some key differences have been discovered between fibromyalgia patients and those without the condition.

Researchers at the University of Michigan in Ann Arbor have found that patients with fibromyalgia have what's called a hyperexcitable nervous system. In other words, pain networks in their brains are more easily activated than people who don't have fibromyalgia. Other researchers have also found impairments in a specific brain region that helps to inhibit the body's response to pain among people with fibromyalgia.

So on the one hand, people with fibromyalgia process any somatic sensory information-for example, light to moderate pressure-as painful, which comes as the result of hyperexcitability in the central nervous system, says pain specialist Miroslav Backonja, M.D., a professor of neurology, anesthesiology, and rehabilitation medicine at the University of Wisconsin School of Medicine and Public Health. Making the problem even worse, the body's pain modulation fails to engage. The body's pain modulation system can help to dial down just how intensely we perceive a painful stimulus.

In this way, fibromyalgia is somewhat similar to epilepsy. There's hyperexcitability in the nervous system on the one hand, and a failure of inhibition on the other, Dr. Backonja says. Which helps explain why pregabalin-a medication that is used to control epilepsy-can also be used to relieve fibromyalgia pain.

Yunxia Wang, M.D., used to be a fibromyalgia-skeptical neurologist as well-until treating a patient with pregabalin helped to change her mind. Four or five years ago, a patient came to see me with a diagnosis of fibromyalgia, says Dr. Wang, a neurologist at the University of Kansas who says that about 15 percent of her practice now involves patients with fibromyalgia. She also had multiple sclerosis. While treating her for MS, I realized that she was using her steroid medication too much. She told me it was because of pain. I wondered if it was because of the fibromyalgia, so I added her on pregabalin without changing her MS treatment. For over a year and a half, she hasn't had an attack and she's doing much better with her pain. So a patient could have an underlying neurologic disease and also have fibromyalgia.

I think there's really been a shift, and the brain imaging is what's doing it, says Matallana. We're seeing changes in the brain in fibromyalgia, and finally the neurologists are saying, 'You're talking my talk. This is interesting and I don't want to be left out.'

Not all neurologists are embracing fibromyalgia, however. It's a difficult condition to take care of. The patients have chronic pain, they call a lot, and they tend to have a lot of comorbidities, says Dr. Kissel. Comorbidities are other conditions that exist alongside the main disorder-with fibromyalgia they often include depression, anxiety, headache, irritable bowel syndrome, chronic fatigue syndrome, lupus, and rheumatoid arthritis. They're very much like chronic headache patients in this regard.

Matallana agrees that the interest in fibromyalgia among neurologists at this point is largely among researchers, pain specialists, and those at academic centers. I don't think it's trickled down to the average neurologist in practice yet, she says. But that may change soon.

 

Same Stimulus, More Pain

These pictures show functional magnetic resonance imaging (fMRI) responses to pressure applied to the left thumb in patients with fibromyalgia versus those without. The chart shows that for fibromyalgia patients, low pressure produced a high pain level (red triangle); for those without fibromyalgia (blue square), similar pressure produced a low level of rated pain. The brain images show common regions of activation in fibromyalgia patients (red) who received low pressure versus non-patients (green) who received high pressure. The similar pain intensities produced by significantly less pressure in the patients resulted in overlapping areas (shown in yellow).

 

Figure. STIMULI RES...
Image Tools

 

OPTIONS FOR TREATMENT

But Dr. Backonja argues that neurologists, especially those who specialize in pain, have a responsibility to take fibromyalgia on. It would be scary and sad for our profession if mounting scientific information were ignored, he says. There's a growing body of information clearly pointing to this as a neurological disorder, and while we can't cure it, there is a pretty reasonable way to apply treatment strategies.

There are now three medications approved by the Food and Drug Administration (FDA) for the treatment of fibromyalgia. In addition to pregabalin, which was the first to gain approval, duloxetine and milnacipran can also be prescribed for fibromyalgia. Duloxetine is also approved for the treatment of depression, anxiety, and painful diabetic neuropathy; and milnacipran for the treatment of depression. Doctors may also prescribe low doses of antidepressants to boost serotonin levels, helping to improve sleep and relieve pain.

In addition to medication, the patient needs to be engaged in figuring out how to help him- or herself, says Dr. Farrar. This can include physical therapy, rehabilitative exercise, yoga, self-hypnosis, biofeedback-things that allow the brain to be retrained to help deal with the pain. None of these are right for everybody, of course. For example, some people prefer exercise therapy to yoga.

How successful are these treatments? For people initially diagnosed with fibromyalgia, Dr. Farrar says that the chances of neurologists being able to help make them at least somewhat better or manage their pain are high-about 75-to 90-percent. By the time someone comes to see a specialist, they have probably had some of the simpler therapies, so the likelihood may have gone down a bit. But we're always able to help people in some way. We work with the patient to focus on what works and what doesn't, helping them to manage their discomfort and disability.

More options are on the horizon, as scientists learn more about pain and the nervous system in general and fibromyalgia in particular. We're learning a lot more about nerve-related pain, and although there aren't any obvious pathways that are focused on fibromyalgia, there are still some new agents that I think will allow us to begin to treat patients for underlying abnormalities, says Dr. Farrar.

He predicts that the prospects for at least two or three additional therapies for fibromyalgia over the next 10 years are very good. That said, people shouldn't set their expectations too high, he says. I doubt we'll be able to get to the point where there is zero pain, but we can make it like arthritis-the pain is there, but people are functional and can do the things they need to do.

-----------

Source: Neurology Now, http://journals.lww.com/neurologynow/Fulltext/2009/05050/Fibromyalgia__Is_Fibromyalgia_Real_.24.aspx 

New Resource for MS: “MS Active Source”

Editor’s Note:  MS is thought to be more prevalent in Gulf War veterans than other people.  Despite repeated calls for such research, VA officials have yet to conduct any studies on the prevalence of MS in Gulf War veterans.

MS ActiveSource provides many excellent tools for managing MS. 

Additionally, the tools may be of interest and value to other Gulf War veterans and those who care for them.

--Anthony Hardie

---------------------------------------------------

MS ActiveSource is a place that offers information to support people living with multiple sclerosis.

Information on MS ActiveSource is updated to provide new ideas for living well and staying active. In short, it is a tool to help you take control of your MS. Here you can use any of your MS ActiveSource tools to build a personalized homepage or connect with a mentor or support.

Whether you are here to seek knowledge or support, MS ActiveSource can be a destination for many of your questions about living well with MS.

 

--------------------------------------

 

Welcome to a place that’s completely devoted to helping you try to live better with your MS. Here you’ll find more ways to stay active, eat healthier, connect with others, and feel better about MS. Have a look.

Register today with MS Active Source and:

  • Receive a free fitness DVD
  • Share your favorite recipe
  • Find memory games and fitness tools
  • Speak with a mentor

Register

----------------------------------------

Source:  MS ActiveSource, http://www.msactivesource.com/

Wednesday, March 9, 2011

USA Today: ALS disease affects bodies, not determination

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease, has affected well over one hundred Gulf War veterans.

According to USA Today article today:

About 40,000 people live with ALS in the USA. That number has grown higher as medical support has extended life expectancy after diagnosis from three years to four-six years, says Stanley Appel, director of the ALS Clinic at the Methodist Hospital in Houston.

Technology has made it possible for ALS patients to stay connected and have productive lives, Appel says.

Like Lester, Cathy Wolf of Katonah, N.Y., and Augie Nieto of Corona del Mar, Calif., are doing that.

Read the full article here:  http://yourlife.usatoday.com/health/medical/managingillness/story/2011/03/ALS-disease-affects-bodies-not-determination/44655194/1?csp=34news&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+usatoday-NewsTopStories+%28News+-+Top+Stories%29&utm_content=My+Yahoo

Tuesday, March 8, 2011

Neurology Now: Articles and Resources on Pain

Editor’s Note:  Chronic widespread pain has long been a commonly reported condition among veterans of the 1991 Gulf War.

And fibromyalgia, a chronic pain condition, is a presumptive condition for VA service-connection for Gulf War veterans.

The following articles from Neurology Now, a consumer-oriented publication for the American Academy of Neurology may be of interest to Gulf War veterans and those who care for them.

A subscription to Neurology Now is free.

--Anthony Hardie

----------------------------------------------------------------------------------------
Resource Central

Neurology Now. 5(2):37-39, March/April 2009.  Where to go for more information on the topics discussed in this issue of Neurology Now and for a directory of patient advocacy organizations.

-------------------------------
More Than a Feeling

GORDON, DEBRA.  Neurology Now. 5(2):18-19,23-25, March/April 2009.  New approaches to diagnosing complex regional pain syndrome are redefining what was once thought of as mystery pain. For years, doctors have viewed some pain patients as having psychological or substance-abuse problems. But that is changing.

-----------------

Expressing Pain

Neurology Now. 4(2):40, March/April 2008.  Expressing pain, a drawing by Eliette Markhbein.

----------------------------
Resource Central

Neurology Now. 4(2):37-39, March/April 2008.  Where to go for more information.

-----------------

On the Front Lines

TALAN, JAMIE.  Neurology Now. 4(2):33-34, March/April 2008.  The army's success in treating injuries in Iraq has led civilian doctors to adopt these new pain-management strategies.

---------------------------
Neuropathy: Not Just Pain

Richardson, Eugene B.  Neurology Now. 4(2):9, March/April 2008.

---------------

Your Questions Answered: MIGRAINE AND FACIAL PAIN

MATHEW, NINAN T.  Neurology Now. 3(6):33, November/December 2007.  Answers to your questions about Lewy body dementia, migraine and facial pain, progressive supranuclear palsy, and dysautonomia.

--------------------------
Mindful Of Pain

HAUPT, JENNIFER.  Neurology Now. 3(6):20-23,27, November/December 2007.  In the fourth installment of our series on Innovative Therapies, we explore the ancient exercises of yoga and tai chi. Emerging evidence-and the experience of practitioners-suggest that these forms of meditation-in-motion can help you harness the mind-body connection to ease the pain of multiple sclerosis, peripheral neuropathy, and other conditions.

Monday, March 7, 2011

Twenty Years Later: Gulf War Coalition Forces

Twenty years ago, military troops from thirty countries came together under a U.N. mandate to forcibly eject Iraqi troops from occupied Kuwait.

A fascinating  breakdown of those troops – almost 1 million in total – is available online from NationMaster.com.   Most, of course, came from the U.S., with almost 697,000 from our country alone.

However, few may remember that Saudi Arabia was second in troop contributions. At 100,000 troops participating in the Coalition, that was more than twice the number of the country in the #3 spot, the United Kingdom, with 45,400 troops.

Egypt, with 33,600 troops, and France, with 14,600, round out the top five.

You can view Gulf War Coalition troop data in a sorted spreadsheet, in a pie chart, or on a world map.

--Anthony Hardie

Neurology Now: Articles on Sleep Disorders

Editor’s Note:  Sleep disorders are a commonly reported condition among veterans of the 1991 Gulf War.

The following articles from Neurology Now, a consumer-oriented publication for the American Academy of Neurology may be of interest to Gulf War veterans and those who care for them.

A subscription to Neurology Now is free.

--Anthony Hardie

----------------------

Hitting the Mattress with MS

PATUREL, AMY.  Neurology Now. 5(1):24-28, January/February 2009.  Many patients with multiple sclerosis also experience sleep disorders, including sleep-related movement disorder, obstructive sleep apnea, central sleep apnea, Rapid Eye Movement (REM) sleep behavioral disorder, and narcolepsy. Sometimes MS is the cause of sleep disorders and sometimes it is a co-existing condition. Here's what you need to know about treatment.

-------------------------
Sleep Apnea Options

Burnett, Jim Sr.  Neurology Now. 3(5):11, September/October 2007.

---------------

Obstructive Sleep Apnea

Neurology Now. 3(3):46-47, May/June 2007.  Where to go for more information.

----------------

Your Questions Answered: SLEEP

Thorpy, Michael.,  Neurology Now. 3(3):38, May/June 2007.  Answers to your questions about Parkinson's, sleep drugs, attention deficit disorder, and Lyme disease.

-------------

Your Questions Answered: SLEEP APNEA

Culebras, Antonio, Neurology Now. 3(1):39, January/February 2007.  Answers on chronic pain, brain arteriovenous malformations, sleep apnea, and Parkinson's disease

----------------

Lullaby and Good Day: Autistic children improving daytime behavior through better sleep

MACREADY, NORRA, Neurology Now. 2(5):40-41, September/October 2006.

-------------

To Read, Perchance to Sleep

Edison, Robin, Neurology Now. 2(5):4, September/October 2006

--------------

Wakeup Call for Insomnia: It's time to treat fragmented sleep like the brain disorder it is

Brey, Robin L., Neurology Now. 2(4):6, July/August 2006.

--------------

Wake-up Call for a Serious Sleep Disorder

Clancy, Frank, Neurology Now. 2(3):38-39, May/June 2006.

Saturday, March 5, 2011

FY10 CDMRP Recommended Proposals Announced

The following twelve proposals were recommended for full funding by the Congressionally Directed Medical Research Program (CDMRP) integration panel in December.  They were publicly announced at last week’s Research Advisory Committee (RAC-GWVI) meetings in Washington, DC.

 

While these twelve represent among the best of those proposed, our panel had a very challenging time selecting from among the many excellent proposals submitted. 

Simply put, the panel could have funded quite a few additional and important treatment-focused studies had there been more funding available.

Future funding for the program will be especially important given that three “consortium” proposals were funded – essentially infrastructure building to enhance the collective efforts of a virtual “Who’s Who” of clinical and scientific researchers actively engaged in unlocking the keys to understanding and treating Gulf War Illness.

--Anthony Hardie

---------------------------------------------

FY10 Consortium Development Awards

  1. Brain-Immune Interactions as the Basis of Gulf War Illness: Consortium Development.   Boston University Medical Campus, Kimberly Sullivan
  2. Integrative Physiology of Gulf War Illness: Role of Autonomic Function, Central Neural Processing, and Sleep.  Veterans Bio-Medical Research Institute, Inc., Jorge Serrador
  3. Gulf War Illness Research Development Consortium (GWIC).  Wright State University, Mariana Morris

 

FY10 Investigator-Initiated Research Awards

  1. Assessment of Diverse Biological Indicators in Gulf War Illness: Are They Replicable? Are They Related?   Baylor University, Lea Steele
  2. Redefining Gulf War Illness Using Longitudinal Health Data: The Fort Devens Cohort.   Boston VA Research Institute, Inc. (BVARI), Maxine Krengel
  3. Proteomic Immune Profiling for the Therapeutic Modulation of Cognitive Impairment in a Novel GWI Mouse Model.  Roskamp Institute, Ghania Ait-Ghezala
  4. Synergistic Actions of Pyridostigmine Bromide and Insecticides on Muscle and Vascular Nociceptors.  University of Florida, Brian Cooper
  5. A Preliminary Trial of Repetitive Transcranial Magnetic Stimulation in Gulf War Veterans With Chronic Multisymptom Illness.  VA Medical Center, Bronx, NY, Julia Golier
  6. Detection of Xenotropic Murine Leukemia Virus- Related Virus (XMRV) in Gulf War Illness: Role in Pathogenesis or Biomarker?   Whittemore Peterson Institute, Judy Mikovits
  7. XMRV and GWI: Is There an Association?   Yale University, Richard Sutton

 

FY10 Innovative Treatment Evaluation Awards

  1. Investigating Clinical Benefits of a Novel Sleep-Focused, Mind-Body Program on Gulf War Illness Symptoms: An Exploratory Randomized Controlled Trial.  University of Utah, Yoshio Nakamura
  2. Nasal Irrigation for Chronic Rhinosinusitis and Fatigue in Patients With Gulf War Syndrome.  University of Wisconsin-Madison, David Rabago

---------------------------------------

CDMRP Disclaimer:

“The [above] list of FY2010 Gulf War Illness Research Program awards represent applications recommended for funding and is for informational purposes only. Identification on the list of applications recommended for funding is not intended to either confer a right to funding nor does it guarantee funding. The award of federal funds to support any of these applications is contingent upon successful negotiations and applicable federal policy.”

----------------------------------------------

More Information:

CDMRP on GWI:  Gulf War Illness (GWI) is characterized by persistent symptoms such as chronic headache, widespread pain, cognitive difficulties, unexplained fatigue, gastrointestinal problems, respiratory symptoms, and other abnormalities that are not explained by traditional medical or psychiatric diagnoses.

This complex set of chronic symptoms may affect as many as 200,000 veterans of the 1990-1991 Gulf War, of the over 700,000 deployed to that region.

The GWIRP focuses its funding on innovative projects that have the potential to make a significant impact on GWI, improving the health and lives of affected service members and their families.

 

Program Vision:  Improve the health and lives of veterans who have Gulf War Illness.

Program Mission:  Fund innovative Gulf War Illness research to identify effective treatments, improve definition and diagnosis, and better understand pathobiology and symptoms.

Neurology Now: FDA Approved First Oral MS Therapy


MS is thought to be more prevalent in Gulf War veterans

Written By Kierstin Wesolowski, Neurology Now

(NeurologyNow) - On Sept. 22, 2010 the FDA approved fingolimod, the first multiple sclerosis (MS) oral therapy, for use in patients with relapsing forms of MS. 

Fingolimod binds to the sphingosine 1-phosphate receptor-1 (SIPI) on some lymphocytes, trapping them in the lymph nodes. It produces a reduction in the number of active T-cells circulating to the CNS, which decreases neuroinflammation and also CNS damage.

“The approval will have a tremendous impact on MS treatment because it offers a new mechanistic approach to the treatment of the disease,” said Bruce A. Cohen, MD, professor of neurology and Director of the MS program at the Feinberg School of Medicine at Northwestern University.

“It also provides an acceptable form of treatment for patients who are unwilling to take current therapeutics or have failed other therapies. Many people have injection phobias and this treatment offers an alternative.”

The MS world has long anticipated fingolimod’s approval, added John Corboy, MD, professor of neurology at the University of Colorado-Denver and co-director of the Rocky Mountain MS Center at Anschutz Medical Campus. “Once we saw the clinical trial data and the FDA review committee’s unanimous recommendation of its approval [in June], it was essentially considered a fait accompli [a fact]that it would be approved.”

The FDA approved the 0.5mg dose of fingolimod based on the results of two phase 3 clinical trials: TRANSFORMS (Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing-Remitting Multiple Sclerosis) and FREEDOMS (FTY720 Oral in Relapsing-Remitting Multiple Sclerosis).

TRANSFORMS investigators randomized 1,292 patients to 0.5mg or 1.25 mg of fingolimod daily, or interferon beta 1A. Researchers found an annualized relapse rate of 0.16 in the 0.5mg group and 0.20 in the 1.25mg cohort (52- and 38-percent relapse reduction rates, respectively).

In FREEDOMS, investigators randomized 1,033 patients to 0.5mg or 1.25mg of fingolimod or placebo. An annualized relapse rate of 0.18 was reported in patients taking 0.5mg of fingolimod compared to 0.16 in patients taking 1.25mg (54- and 60-percent relapse reduction rates, respectively).

(Read the Feb. 18, 2009 Neurology Today story, “Two Oral Therapies Found Effective for MS” in print and online http://bit.ly/aqdmCy)

The FDA advised that patients using fingolimod be monitored for bradycardia during the first six hours of being given the drug, according to an FDA news release. In addition, patients should receive an ophthalmologic evaluation prior to starting treatment due to the risk of developing macular edema, which occurred in some patients. (See “Possible Adverse Events”)

EXPERTS COMMENT
“We haven’t seen any specifics from the FDA or [fingolimod manufacturer, Novartis] on how to do the monitoring,” said Dr. Corboy. “Can the patient be left alone in the office for six hours, or do they need to be hooked up to telemetry, where they’re having a continuous EKG? And does an EKG need to be done on all patients, or only those with a history of heart disease?”

He added that most of these decisions will most likely have to be made according to individualized practices.   

Aaron E. Miller, MD, chief medical officer of the National MS Society and director of the MS Center at Mt. Sinai Medical Center in New York City, said he will prescribe fingolimod conservatively as more safety data are gathered during the post-marketing period. However, “if the safety profile looks good, then almost any patient with the relapsing form of MS would be a good candidate” for its use. Even patients who are doing well on their injectable forms of disease-modifying therapy, he added. 

Dr. Cohen advised that neurologists will have to be cognizant of possible later emerging side effects that weren’t identified in the clinical trials and may come to light with more widespread use of the agent. 

All the experts who spoke to Neurology Now were encouraged by fingolimod’s approval and its subsequent impact on MS treatment.

“The treatments that we presently have aren’t as good as we would like them to be: they aren’t cures, and they’re not tolerated or adequate enough for a variety of patients,” said Dr. Corboy. “I’m happy to have another treatment option available and look forward to learning more about it as it goes into general use. I anticipate it will have a significant role in the armamentarium in treating MS patients.”

POSSIBLE ADVERSE EVENTS
The following are possible adverse events associated with fingolimod. Dr. Corboy noted that the majority of these side effects were more significant at the higher, 1.25mg dosage, which was not approved by the FDA.

• Bradycardia
• Heart Block
• Increased blood pressure
• Macular edema
• Restrictive lung disease
• Liver function abnormalities
• Headache
• Influenza and other infections

REFERENCES

  • Kappos L, Radue EW, Burtin P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; E-pub 2010 20 Jan.
  • Cohen JA, Barkhof F, Kappos L, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; E-pub 2010 20 Jan.

------

Source:  Neurology Now, http://journals.lww.com/neurologynow/blog/breakingnews/pages/post.aspx?PostID=16

Tuesday, March 1, 2011

RAC Meeting Spotlights Progress, Problems

 

This week’s meetings of the VA Research Advisory Committee on Gulf War Veterans’ Illnesses (RAC-GWVI) highlighted significant progress in treatment- and diagnostic-focused research through a large panel discussion with more than dozen active VA and non-VA researchers.

“You do science.  But you’re bringing hope,” I said to the researchers on the panel.

Their research ranges from potential treatments to “diagnostic markers” for ill Gulf War veterans. 

One of the researchers presented advances with a national brain bank to allow for future study of donated brains and spinal cords of Gulf War veterans who die.

At the same time, the meetings shone a spotlight serious lingering problems related to a lack of a research strategic plan and failure to implement much of the recommendations VA’s internal task on Gulf War veterans.

Serious issues remain with a proposed national VA survey of roughly 30,000 Gulf War veterans.  The RAC requested VA to hold off on the survey until the RAC’s recommendations are included.

--Anthony Hardie